Literature DB >> 16998932

Extrapulmonary small cell cancer: a Canadian province's experience.

Kamal Haider1, Rabia K Shahid, Daygen Finch, Amer Sami, Imran Ahmad, Sunil Yadav, Riaz Alvi, David Popkin, Shahid Ahmed.   

Abstract

BACKGROUND: The objective of this study was to determine variables that correlate with the survival of patients with extrapulmonary small cell carcinoma (EPSCC).
METHODS: Medical records of 101 eligible patients with EPSCC who were diagnosed in Saskatchewan from 1971 to 2002 were reviewed. Survival was calculated by using the Kaplan-Meier method. A logistic regression analysis with a backward elimination was carried out to determine prognostic variables that predicted mortality.
RESULTS: The median patient age was 72 years (range, 24-100 years), and the male-to-female ratio was 1.4:1. The primary disease sites were as follows: breast, 9%; gastrointestinal, 20%; genitourinary, 18%; gynecologic, 11%; head and neck, 10%; thymus, 2%; and unknown primary site, 31%. Fifty-one patients had limited disease (LD), and 50 patients had extensive disease (ED). Patients with LD had a median overall survival of 34 months (range, 0.2-276 months) compared with 2 months (range, 0.1-108 months) in patients with ED (P < .0001). Among different primary sites, patients with gynecologic small cell cancer (SCC) had a median survival of 54.4 months, whereas patients with SCC of an unknown primary site had a survival of 2.5 months. Among various variables that were examined with respect to their prognostic importance, an abnormal white blood cell count (odds ratio [OR], 6.9; 95% confidence interval [95% CI], 3.4-14.1), an Eastern Cooperative Oncology Group performance status >2 (OR, 4.5; 95% CI, 2.1-9.9), and ED (OR, 2.7; 95% CI, 1.4-5.0) were found to be correlated significantly with mortality.
CONCLUSIONS: The gastrointestinal and genitourinary tracts were the 2 major sites involved by EPSCC in the current series. Survival varied according to the primary sites, and patients with gynecologic tumors had the best prognosis. An abnormal white blood cell count, a poor performance status, and disease extent were important factors in predicting survival. (c) 2006 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 16998932     DOI: 10.1002/cncr.22235

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

1.  Mixed exocrine and endocrine carcinoma in the stomach: a case report.

Authors:  Han Hong Lee; Chan Kwon Jung; Eun Sun Jung; Kyo Young Song; Hae Myung Jeon; Cho Hyun Park
Journal:  J Gastric Cancer       Date:  2011-06-30       Impact factor: 3.720

Review 2.  Primary cutaneous small-cell carcinoma: a case report.

Authors:  Berna Bozkurt Duman; Ismail Oğuz Kara; Meral Günaldi; Vehbi Erçolak
Journal:  Med Oncol       Date:  2010-09-08       Impact factor: 3.064

Review 3.  Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature.

Authors:  Christopher S R Dakhil; Jo A Wick; Anup Kasi Loknath Kumar; Megha Teeka Satyan; Prakash Neupane
Journal:  Med Oncol       Date:  2014-08-24       Impact factor: 3.064

4.  Limited disease of extra-pulmonary small cell carcinoma. Impact of local treatment and nodal status, role of cranial irradiation.

Authors:  A C Müller; C Gani; M Weinmann; F Mayer; B Sipos; M Bamberg; F Eckert
Journal:  Strahlenther Onkol       Date:  2012-03       Impact factor: 3.621

5.  Retrospective review of extra-pulmonary small cell carcinoma and prognostic factors.

Authors:  Jonathan Edward Brammer; Premal Lulla; Garrett Rushing Lynch
Journal:  Int J Clin Oncol       Date:  2013-10-12       Impact factor: 3.402

6.  Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Authors:  Patricia Moretto; Lori Wood; Urban Emmenegger; Normand Blais; Som Dave Mukherjee; Eric Winquist; Eric Charles Belanger; Robert Macrae; Alexander Balogh; Ilias Cagiannos; Wassim Kassouf; Peter Black; Piotr Czaykowski; Joel Gingerich; Scott North; Scott Ernst; Suzanne Richter; Srikala Sridhar; M Neil Reaume; Denis Soulieres; Andrea Eisen; Christina M Canil
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

7.  Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate.

Authors:  Jonathan Edward Brammer; Premal Lulla; Garrett Rush Lynch
Journal:  Int J Clin Oncol       Date:  2011-02-24       Impact factor: 3.402

8.  Incidental finding of a small cell neuroendocrine carcinoma of the ureter.

Authors:  Obinna Obi-Njoku; Chris Bell; Prashant Ravindran Menon; Iqbal Shergill
Journal:  BMJ Case Rep       Date:  2019-08-01

9.  Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans.

Authors:  Christopher N Hueser; Nghi C Nguyen; Medhat Osman; Necat Havlioglu; Anjali J Patel
Journal:  World J Surg Oncol       Date:  2008-09-25       Impact factor: 2.754

10.  The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004.

Authors:  Yien Ning S Wong; Ruth H Jack; Vivian Mak; Møller Henrik; Elizabeth A Davies
Journal:  BMC Cancer       Date:  2009-06-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.